Dr. John Dixon


John Dixon is a medicinal chemist with over 30 years’ experience in research and development within the pharmaceutical industry. He was Head of Medicinal Chemistry at Fisons, Vice President of Preclinical R&D and Vice President of Drug Discovery at AstraZeneca Charnwood, where he delivered the marketed anti-thrombotic drugs Brilinta and Cangrelor. Upon retirement from AstraZeneca in July 2008, John became Director of JD International Consulting Ltd, consulting on most aspects of drug discovery and early development in most therapy areas with a worldwide client base. He currently holds Board positions with Xenogesis and Sentinel Oncology.